D. Ross Camidge Discusses The Development Of A New Lung Cancer Drug

D. Ross Camidge Discusses the Development of a New Lung Cancer Drug

Dr. Camidge Discusses Treatment of Patients With ALK+ NSCLC

D. Ross Camidge Discusses Brain Metastases in Patients With Lung Cancer

Dr. Ross Camidge Discusses Resequencing Lung Cancer

Dr. D. Ross Camidge on Targeted Therapies in Adjuvant Non-Small Cell Lung Cancer

Dr. Ross Camidge on the Ever Changing World of Clinical Cancer Research

Dr. Ross Camidge Discusses Crizotinib in ROS1 Rearranged NSCLC

Targeted Oncology

Dr. Camidge on Optimal Therapy in EGFR+ NSCLC

Be Lung Aware: Lung Cancer Screening in the UAE

MCO Healthcare Conferences

Dr. Ross Camidge Discusses Next-Generation Sequencing

Dr. Camidge on the ALTA Study of Brigatinib in NSCLC

MET as a Secondary Driver in Lung Cancer

Targeted Oncology

Dr. Camidge on MET as a Target in Lung Cancer

Dr. Camidge on Phase I Study With AZD9291 in NSCLC

Dr. Camidge on the Unmet Needs for Lung Cancer

The ROS1ders Interview Dr Ross Camidge 16 May 2019

Dr. Camidge on Crizotinib as a ROS1 Inhibitor in NSCLC

Mechanisms of Resistance to TKI in NSCLC

Targeted Oncology

Dr. Camidge on AP26113 in Patients with Advanced Malignancies

Using emibetuzumab directed towards MET for the treatment of lung cancer